Prostate cancer develops when the male sex hormone testosterone stimulates prostate tumors to grow. Abiraterone Acetate is an innovative drug treatment for metastatic prostate cancer after unsuccessful chemotherapy sessions. Dr. Lindsay Rosenwald has supported the initiatives to fast-track the research development of this new class of medication. He aims to provide cure to patients who had no good clinical therapies available to them. He wants to offer a potent alternative and safe life-prolonging treatment for men with advanced prostate cancer who have failed chemotherapy.
But as the population increases, chances are great that the rate of prostate cancer cases will increase as well. Dr. Lindsay Rosenwald, primarily focused on biotechnology and pharmaceutical industry, has established a company that is solely based on a compound popularly known as Abiraterone Acetate. Being committed to discovering innovative ways of transforming the healthcare industry, he shares his opinions and says that Abiraterone Acetate is one of the most promising candidates for an aggressive stage of prostate cancer treatment.
Abiraterone Acetate, however, still has some unclear points. The compound was at the Phase III trial and was also being compared with a new cancer treatment named Provenge, which has been proven effective against metastatic prostate cancer. But with the notable and continuous investments of Dr. Lindsay Rosenwald, Abiraterone Acetate with its strong capability of curing a fatal disease like prostate cancer was bought by Johnson & Johnson in 2004. J&J offered the drug to some patients with certain criteria creating a significant improvement in the survival statistics.